Discover
ESPR
Esperion Therapeutics, Inc.
3.16
100 x 3.15
2 x 4.05
bid
ask
+
0.00
0.00%
51 @ 04:57 AM
3.17 +0.01 (0.32%)
| Ytd | -14.59% | |
| 1y | 216.00% |
3.15
day range
3.17
1.00
52 week range
4.18
| Open | 3.17 | Prev Close | 3.16 | Low | 3.15 | High | 3.17 | Mkt Cap | 814.31M |
| Vol | 5.38M | Avg Vol | 13.19M | EPS | N/A | P/E | N/A | Forward P/E | 11.20 |
| Beta | 0.95 | Short Ratio | 5.70 | Inst. Own | 66.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 2.95 | 200-d Avg | 3.04 | 1yr Est | 7.51 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.14 | -0.15 | -0.01 | -7.14% |
| 2024-08-12 | 2024-06 | -0.15 | -0.05 | 0.1 | 66.67% |
| 2024-05-07 | 2024-03 | -0.08 | 0.34 | 0.42 | 525.00% |
| 2024-02-27 | 2023-12 | -0.53 | -0.5 | 0.03 | 5.66% |
| 2023-11-07 | 2023-09 | -0.42 | -0.37 | 0.05 | 11.90% |
| 2023-08-01 | 2023-06 | -0.63 | -0.46 | 0.17 | 26.98% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2024-12-13 | Needham | Upgrade | Buy | Buy |
| 2024-12-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-22 | CARROLL J MARTIN | Director | 64.65K | Stock Award(Grant) |
| 2024-05-22 | FISCHER SETH H Z | Director | 28.15K | Stock Award(Grant) |
| 2024-07-16 | FOODY JOANNE MICALE | Officer | 272.86K | Sale |
| 2024-05-22 | FUHRMAN ALAN CPA | Director | 53.40K | Stock Award(Grant) |
| 2024-05-22 | GOTTO ANTONIO M JR | Director | 51.60K | Stock Award(Grant) |
| 2024-12-16 | HALLADAY BENJAMIN | Chief Financial Officer | 240.69K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Wasatch Advisors LP | 23.35M | 52.30M | 11.85% |
| 2024-09-29 | Blackrock Inc. | 14.26M | 31.95M | 7.24% |
| 2024-09-29 | Vanguard Group Inc | 13.04M | 29.22M | 6.62% |
| 2024-09-29 | Bellevue Group AG | 9.94M | 22.27M | 5.05% |
| 2024-09-29 | Two Seas Capital Lp | 6.58M | 14.75M | 3.34% |
| 2024-09-29 | Geode Capital Management, LLC | 4.33M | 9.70M | 2.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Wasatch Ultra Growth Fund | 6.68M | 14.95M | 3.39% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 6.18M | 13.84M | 3.14% |
| 2024-10-30 | iShares Russell 2000 ETF | 4.87M | 10.90M | 2.47% |
| 2024-09-29 | Wasatch Small Cap Growth Fund | 4.40M | 9.85M | 2.23% |
| 2024-09-29 | Wasatch Microcap Fund | 4.21M | 9.43M | 2.14% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 2.58M | 5.77M | 1.31% |